Tokyo, Sept. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062752) titled 'Survival and Long-Term Outcomes in Individuals with Campomelic Dysplasia: A Systematic Review' on Aug. 31.
Study Type:
Others,meta-analysis etc
Primary Sponsor:
Institute - National Center for Child Health and Development
Condition:
Condition - Campomelic dysplasia
Classification by malignancy - Others
Genomic information - YES
Objective:
Narrative objectives1 - What are the characteristics and the survival outcomes of patients with campomelic dysplasia?
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Types of studies: We will include observational studies (prospective or retrospective cohort studies, case-control studies, cross-sectional studies), case series, and case reports that report survival, mortality, or long-term clinical outcomes in individuals with campomelic dysplasia. Conference abstracts without sufficient outcome data, review articles, editorials, letters without original patient data, and animal or laboratory studies will be excluded. Only studies published in English and Japanese will be included. No restrictions will be applied regarding publication year.
Participants: Individuals of any age with a diagnosis of campomelic dysplasia, established clinically and/or confirmed by genetic testing (e.g., pathogenic variants in the SOX9 gene).
Key exclusion criteria - Studies were excluded if they involved fetal cases, non-human subjects, or cases with unavailable or unknown clinical outcomes.
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 04 Month 17 Day
Date of IRB - 2026 Year 04 Month 17 Day
Anticipated trial start date - 2026 Year 04 Month 17 Day
Last follow-up date - 2027 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071807
Disclaimer: Curated by HT Syndication.
